Overview
Americans for Ibogaine (AFI) is a U.S.‑based advocacy and policy organization focused on expanding medically supervised access to ibogaine by catalyzing FDA‑pathway clinical trials, coordinating stakeholder coalitions, and educating policymakers and the public.[1][2]
AFI places particular emphasis on veteran populations, harm‑reduction, and translating international clinical experience into standardized U.S. research protocols.[2][3]
Mission and Activities
AFI’s stated mission is to support rigorous clinical development of ibogaine‑based therapies, advocate for state and federal research funding, and build coalitions of veterans, clinicians, researchers and legislators to design safe access pathways.[1][2]
- Policy engagement and legislative drafting to fund research and create trial consortia.[2]
- Public education and dissemination of peer‑reviewed and real‑world evidence supporting clinical trials.[1]
- Coordination with veterans’ groups and academic partners to prioritize indications such as PTSD and traumatic brain injury (TBI).[3]
Scientific background and mechanisms
Ibogaine is a naturally occurring indole alkaloid derived from the root bark of Tabernanthe iboga used traditionally in Bwiti ceremonies in Central and West Africa.[4][5]
Pharmacologically, both ibogaine and its primary human metabolite noribogaine act on multiple targets including NMDA receptors, monoaminergic transporters (notably serotonin), opioid receptor subtypes, and ion channels; noribogaine’s longer half‑life and distinct profile are considered central to sustained clinical effects reported in human and animal studies.[4][5]
Preclinical data also report modulation of neuroplasticity markers (for example, BDNF) and reductions in drug self‑administration in animal models, findings that underpin hypotheses for therapeutic effects in addiction and mood disorders.[5][4]
Clinical evidence
The clinical literature for ibogaine is heterogeneous and includes open‑label trials, case series, observational clinic reports, and a small number of academic human studies; randomized, placebo‑controlled trials remain scarce.[4][5]
AFI emphasizes a 2024 academic study conducted with U.S. veterans. Special Operations veterans that reported short‑term reductions in PTSD, depression, and anxiety symptoms following a supervised ibogaine protocol delivered in Mexico, which AFI cites as a proof‑of‑concept for controlled research in the U.S.[3][2]
Historical observational reports and case series describe reductions in opioid withdrawal and craving after single high‑dose treatments, but these data are uncontrolled and variable in follow‑up duration, which AFI and independent reviewers note as a reason for formal trials.[5][4]
For related summaries of ibogaine in PTSD and addiction, see Ibogaine for PTSD: A Research Overview and Ibogaine for Opioid Addiction.[3][5]
Safety, adverse effects and mitigation
Major safety concerns with ibogaine identified in the literature include cardiotoxicity (notably QT interval prolongation and rare reports of torsades de pointes), seizures, ataxia, hepatotoxicity in isolated reports, and intense acute psychological effects; several deaths have been reported in unsupervised or poorly screened settings.[4][5]
Regulatory caution grew after a U.S. National Institute on Drug Abuse (NIDA) program was halted in the 1990s following an unexpected death during early clinical development, a history AFI acknowledges while advocating for updated safety protocols.[4][5]
AFI and recent academic projects stress risk mitigation through comprehensive pre‑screening (ECG, electrolyte and medication review), continuous cardiac monitoring during dosing, exclusion of unstable cardiac disease and interacting medications, and adjunctive measures such as magnesium supplementation as used in some protocols.[2][3]
Legal and policy landscape
Federally in the United States, ibogaine is classified as a Schedule I substance, a status that restricts routine clinical use and necessitates regulatory pathways (e.g., IND applications) for research.[4]
Because of federal scheduling, much of the contemporary clinical experience with ibogaine has occurred in international clinics and research sites where local laws permit medical use or limited research; AFI documents patient travel and cross‑border treatment as evidence of unmet medical need and regulatory friction.[2][5]
In 2025, Texas enacted legislation and appropriated state funding to support ibogaine research, a high‑profile state investment AFI cites as a model for building U.S. trial capacity; reporting describes a $50 million state fund and SB 2308 as key enabling actions.[6][2]
Advocacy strategy and notable achievements
AFI’s strategy combines coalition building (veterans, researchers, clinicians, legislators), public education, and targeted state policy campaigns to create fora for FDA‑compatible research and to secure public funding for trials.[1][2]
AFI identifies the Stanford veterans study (published as an academic report and covered in institutional press) and the Texas state investment as signature events that d